Proactive Investors - Run By Investors For Investors

ReNeuron eyes profits after sustained efficacy in blindness treatment

ReNeuron Group PLC (LON:RENE) shares rose on Thursday after the group said its cell therapy for blindness-causing disease Retinitis Pigmentosa went well in the first group of phase II patients receiving the treatment. ReNeuron CEO Michael Hunt tells Proactive London the milestone announcement is significant but really only a taste of what's to come. News here too on ReNeuron's stroke efficacy treament and how the company intends to develop throughout 2019.
The RP announcememt comes after February’s update when the first three patients taking part in the phase I/II study were able to read an additional three lines of a standard eye chart.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use